This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grodzki, M. Articles by Zehbe, I. Search for Related Content PubMed PubMed Citation Articles by Grodzki, M. Articles by Zehbe, I. Related Collections Risk Assessment Risk Assessment: Biomarkers

Increased Risk for Cervical Disease Progression of French Women Infected with the Human Papillomavirus Type 16 E6-350G Variant

¹ Johannes Gutenberg University, Medical Microbiology, Mainz, Germany; ² Laboratoire Pol Bouin, Hopital Maison Blanche, CHU, Reims, France; ³ IARC, Lyon, France; and ⁴ Thunder Bay Regional Health Sciences Centre, Regional Cancer Care, Thunder Bay, Ontario, Canada

Requests for reprints: Ingeborg Zehbe, Thunder Bay Regional Health Sciences Centre, Regional Cancer Care Programme, 980 Oliver Road, Thunder Bay, Ontario P7B 6V4, Canada. Phone: 807-684-7256; Fax: 807-684-5806. E-mail: zehbei{at}tbh.net

To test the significance of human papillomavirus (HPV) type 16 and HPV16 E6 variants as risk factors for viral persistence and progression to high-grade lesion, we did a nested case-control study within a cohort study of >15,000 Caucasian French women. Three groups infected with high-risk HPV were compared: (a) women with cleared infection (controls, n = 201), (b) women with persistent infection (cases, n = 87), and (c) women who progressed into high-grade lesion (cases, n = 58). Women with persistent HPV infection and those that progressed into high-grade lesions were likelier to harbor HPV16 than other high-risk HPV types [odds ratio (OR), 2.4; 95% confidence interval (95% CI), 1.3-4.3 and OR, 4.2; 95% CI, 2.2-8.1, respectively]. Notably, especially elevated ORs of persistence (3.0; 95% CI, 1.4-6.7) and progression (6.2; 95% CI, 2.7-14.3) were found among women who harbored the HPV16 350G variant. Thus, HPV type and HPV16 variant seem to be risk factors for viral persistence and progression of infections into high-grade cervical lesions. Cancer Epidemiol Biomarkers Prev 2006:15(4);820–2

This article has been cited by other articles:

				U. A. Hasan, E. Bates, F. Takeshita, A. Biliato, R. Accardi, V. Bouvard, M. Mansour, I. Vincent, L. Gissmann, T. Iftner, et al. TLR9 Expression and Function Is Abolished by the Cervical Cancer-Associated Human Papillomavirus Type 16 J. Immunol., March 1, 2007; 178(5): 3186 - 3197. [Abstract] [Full Text] [PDF]

				Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1240 - 1240. [Full Text] [PDF]